8-K filed Feb 26, 2026 at 08:02 ET
Novavax reported strong financial results for Q4 and full year 2025, with revenue up 67% YoY to $147 million in Q4 and $1.12 billion for the full year, driven by Sanofi milestones and licensing revenue. The company also announced a major non-exclusive license agreement with Pfizer for its Matrix-M adjuvant technology, receiving a $30 million upfront payment and potential for up to $500 million in milestones. Despite a cash balance decline to $751 million, Novavax secured a $330 million credit facility and guided to $230-$270 million in adjusted revenue for 2026.